Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid,
Saved in:
Main Authors: | Agoritsa Gravani (Author), Panagiota Christou (Author), Stelios Tigas (Author), Ioannis D. Bassukas (Author) |
---|---|
Format: | Book |
Published: |
Sociedade Brasileira de Dermatologia,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading
by: Hiroyuki Takama, et al.
Published: (2018) -
Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid
by: Outi Lindgren, et al.
Published: (2019) -
Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
by: Kamran Balighi, et al.
Published: (2022) -
Pemphigoid nodularis induced by long-term use of dipeptidyl peptidase-4 inhibitors
by: Natsumi Norikawa, et al.
Published: (2023) -
Serum autoantibodies against the extracellular region of α6β4 integrin in a patient with dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid
by: Chigusa Yamashita, MD, et al.
Published: (2022)